<![CDATA[Hansa Biopharma Reports Fourth Quarter and Full Year 2024]]>Hansa Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results

Link Preview Image
Hansa Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results | Hansa Biopharma

favicon

(www.hansabiopharma.com)

]]>https://dev.proinvestor.com/forum/topic/447042/hansa-biopharma-reports-fourth-quarter-and-full-year-2024RSS for NodeSun, 14 Jun 2026 15:09:53 GMTThu, 06 Feb 2025 05:15:44 GMT60<![CDATA[Reply to Hansa Biopharma Reports Fourth Quarter and Full Year 2024 on Thu, 06 Feb 2025 06:22:48 GMT]]>Hansa Biopharma: Ends 2024 on a softer note

Research Note 2025-02-06 08:15

After a period of steady increase in both European Idefirix sales and patient usage, Hansa records a softer Q4, with sales limited to SEK 25.6m. Hansa does not expect to record any material provisions related to retroactive discounts after 2024. Hansa enters 2025 with a more significant number of centres using Idefirix and improved support from European guidelines.

Just a moment...

favicon

(www.redeye.se)

]]>https://dev.proinvestor.com/forum/post/9491585https://dev.proinvestor.com/forum/post/9491585Thu, 06 Feb 2025 06:22:48 GMT<![CDATA[Reply to Hansa Biopharma Reports Fourth Quarter and Full Year 2024 on Thu, 06 Feb 2025 05:58:16 GMT]]>Year-end Report

https://www.hansabiopharma.com/files/Main/1219/4101367/20250206-hansa-biopharma-q4-and-fy-2024-report.pdf

]]>https://dev.proinvestor.com/forum/post/9491600https://dev.proinvestor.com/forum/post/9491600Thu, 06 Feb 2025 05:58:16 GMT